Spero Therapeutics opened higher at $1.03, compared with its previous close of $1.02. In the last trading session, the stock traded between $1.00 and $1.03. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Spero Therapeutics is now worth
$ 5.97
Resulting in a loss of
$ 94.03 (94.03%)
Note: Past profits do not guarantee future returns.
Rating from 1 Analysts
Today's Change
$-0.01 (-0.98%)
Day High
$1.03
Day Low
$1.00
Day Open
$1.03
Prev Close
$1.02
Volume
3,11,179
1W Return
-5.16%
1M Return
-14.77%
3M Return
-18.22%
6M Return
-60.39%
1Y Return
-61.45%
Market Cap ($ Mn)
59
PE Ratio
8.57
PB Ratio
1.58
PEG Ratio
1.63
ROE
21.62%
ROCE
12.26%
EPS (TTM)
$-0.16
1 Week
-5.16%
1 Month
-14.77%
3 Months
-18.22%
6 Months
-60.39%
9 Months
-57.38%
Spero Therapeutics CEO to lead fireside chat at Chardan Healthcare Conference
Esther Rajavelu to present at Chardan 10th Annual Healthcare Conference. Fireside chat scheduled for October 20, 2026, at 9:15 am ET. Webcast replay available for approximately 90 days post-event.
28 days agoSpero Therapeutics grants 556,000 equity awards to new hires
Issued 233,000 RSUs and 323,000 stock options to new employees. Awards granted under 2019 Inducement Equity Incentive Plan per Nasdaq Rule 5635(c)(4). Stock options vest 25% at one year, then monthly over three years. RSUs vest in four equal annual installments starting at one year.
1mo agoSpero Therapeutics to present at H.C. Wainwright healthcare conference
Esther Rajavelu, CEO of Spero Therapeutics, will present at the H.C. Wainwright 28th Annual Global Healthcare Conference. The presentation is scheduled for September 15, 2026, at 1:30 pm ET in New York City. The conference runs from September 14 to 16, 2026, with leadership available for one-on-one meetings. Spero’s lead program, SP001, is a third-generation anti-CD40L monoclonal antibody for immune-mediated diseases.
2mo agoSpero Therapeutics files prospectus to offer up to $300 million in securities
Spero Therapeutics filed an SEC prospectus for a new offering. The company plans to offer up to $300 million in securities. No additional financial or operational details were provided.
2mo agoSpero Therapeutics licenses SP001 from Innovent for $1.1bn
Spero Therapeutics has secured exclusive global rights, excluding Greater China, to Innovent Biologics' SP001 (IBI355) in a deal worth approximately US$1.1 billion. The agreement includes upfront payments, milestones, and royalties, with Spero planning a Phase 2 trial for IgG4-related disease in Q2 2027 and Innovent targeting Sjögren’s disease in China by early 2027.
4mo agoSpero Therapeutics secures $105M royalty financing for SP001
Spero Therapeutics secured $105 million in non-recourse, non-dilutive financing through a royalty transaction with affiliates of Healthcare Royalty, a business of KKR. The proceeds will primarily support the Phase 2 development of SP001, an immunology drug candidate in-licensed from Innovent Biologics. The transaction monetizes future milestone and royalty payments associated with Utebzi, extending the company's cash runway guidance into the second half of 2029.
4mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Spero Therapeutics is now worth
$ 5.97
Resulting in a loss of
$ 94.03 (94.03%)
Note: Past profits do not guarantee future returns.
